International League Against Epilepsy in 2001, and had no underlying etiology. According to therapeutic efficacy, these patients were divided into two groups, which were non-resistant epilepsy subgroup (n = 29) and drug-resistant subgroup (n = 23). Patients in the drugresistant subgroup have taken a variety of anti-epilepsy drugs with the outcome of having no response to them. Patients in the nonresistant epilepsy subgroup responded to at least one AED. The age, gender, clinical phenotype, duration of the illness and AEDs prescribed to the patients are presented in Table 1 . We studied only patients whose last presenting seizure was within 1 week before the CSF was taken, to avoid interference from recent seizure outbreaks. In addition, 20 age-and gender-matched individuals (11 males, 9 females) with a mean age of 36.15 AE 15.82 years were used as controls. All controls had no history of neuropsychological diseases nor an exposure to antiepileptic drugs. Tables 2 and 3 present the clinical data of all participants. Informed consent was obtained from all participants. 4 ml CSF and 5 ml venous blood were collected from patients and controls. The total protein and biochemistry of CSF and blood were analyzed, and remaining CSF was centrifuged at 2000 rpm for 10 min at 4 8C to separate cell components, the remaining blood was centrifuged at 3000 rpm for 15 min to collect the serum. All samples were stored at À80 8C for later analysis.
Ethics
This trial was approved by the ethics committee on human research at Chongqing Medical University.
Enzyme-linked immunosorbant assays (ELISA)
CSF SOD1 was determined using ELISA, with the Human SOD1 Elisa Kit (Uscn Life Science & Technology Company, Wuhan, China), following the manufacturer's instructions. Dilution of the serum and CSF were 1:10 and 1:5, respectively. The assay procedure was as follows: add 100 ml of standard, blank, and samples per well and incubate for 2 h at 37 8C covering with plate sealer. Then remove the liquid from each well and add 100 ml detection reagent A working solution to each well and incubate for 1 h at 37 8C. Then aspirate each well and wash by filling each well with wash buffer using multichannel pipettor, repeating the process three times. After that, add 100 ml detection reagent B working solution to each well and incubate for 1 h at 37 8C and repeat the aspirate and wash steps. Then add 90 ml substrate solution to each well and incubate for 30 min at 37 8C, protecting from light. Add 50 ml stop solution to each well, if color change does not appear uniform. Finally, determine the optical density of each well at once, using a microplate reader set to 450 nm on Multiscan Spectrum Microplate Spectrophotometer (Thermo Fisher Scientific, USA).
Statistical analysis
Descriptive data were expressed as means AE standard deviation (S.D.). Independent sample t-test and one-way analysis of variance (ANOVA) were used. A P-value less than 5% was considered as significant. Statistical analysis was performed using SPSS statistics software, version 11.5.
Results
CSF-total protein was 0.41 AE 0.15 g/l in the non-resistant epilepsy subgroup, 0.45 AE 0.23 g/l in the drug-resistant epilepsy subgroup, and 0.47 AE 0.09 g/l in the controls. Serum-total protein was 61.66 AE 4.22 g/l in the non-resistant epilepsy subgroup, 62.35 AE 3.46 g/l in the drug-resistant epilepsy subgroup, and 61.30 AE 3.80 g/l in the controls. The total protein of CSF and serum had no significant difference in the non-resistant, drug-resistant patients subgroup and control group (P > 0.05).
The concentration of CSF-SOD1 was 0.13 AE 0.12 ng/ml in the drug-resistant subgroup, 0.29 AE 0.23 ng/ml in the non-resistant epilepsy subgroup, and 0.40 AE 0.35 ng/ml in the controls. One-way ANOVA analysis showed that the difference between the three groups was significant (P < 0.05). Dunnett-t test showed that the concentration of CSF-SOD1 in the drug-resistant epilepsy subgroup was lower than that in the controls (P < 0.05), and there was no significant difference of concentration of CSF-SOD1 between the non-resistant epilepsy subgroup and the controls (P > 0.05). There was a significant difference of CSF-SOD1 between the drug-resistant epilepsy subgroup and the controls. Serum-SOD1 level was 29.66 AE 9.09 ng/ml in the drug-resistant group, 42.74 AE 13.88 ng/ml in the non-resistant epilepsy subgroup, and 33.48 AE 14.87 ng/ml in the controls. One-way ANOVA analysis showed that there were significantly differences between the three groups (P < 0.05). Dunnett-t test showed serum-SOD1 level in the drug-resistant subgroup was not significantly lower than that in the controls (P > 0.05). No statistically significant difference was found between the non-resistant epilepsy subgroup and the controls (P > 0.05). The significant difference of serum-SOD1 existed between the drug-resistant epilepsy subgroup and the drug-effective epilepsy subgroup.
Discussion
The present study indicates that the SOD1 concentration is decreased in the CSF of patients with epilepsy, and decreased CSF-SOD1 is more obvious in the subgroup of drug-resistant epilepsy than that in the non-resistant epilepsy subgroup and the controls. To our knowledge, our group firstly reported the alterations of CSF-SOD1 in patients with epilepsy.
The human SOD1 gene is located on chromosome 21q22.11. The protein encoded by this gene binds copper and zinc ions and responds to destroy free superoxide radicals in the body. The encoded soluble cytoplasmic protein acts as a homodimer to convert naturally occurring but harmful superoxide radicals to molecular oxygen and hydrogen peroxide. Mutations in this gene have been implicated as causes of familial amyotrophic lateral sclerosis.
2 SOD1 works as a multifunctional protein, associated with oxidative stress, excitotoxicity, mitochondria dysfunction. 7 In the present study, decreased CSF-SOD1 level shows that the SOD1 protective function is attenuated in response to epilepsy. Mutations of the SOD1 gene contribute to neuronal injuries in the cerebrum, brain stem and spinal cord, and to enhancement of oxidizing reaction, and thus misfolded proteins, triggering familial amyotrophic lateral sclerosis. 8 In addition, SOD1 also participates in apoptosis, including nitric oxide-dependent and mitochondriadependent. 9,10 Therefore, SOD1 is an important factor in neuronal apoptosis. It is well established that apoptosis and oxidative stress are important pathophysiological processes in the development of epilepsy, 11, 12 and decreased SOD1 means attenuation of antioxidative and anti-apoptotic activities via various transcriptional pathways, 13 contributing to development of epilepsy.
Although this study has found that SOD1 is decreased in the CSF of patients with epilepsy, it is impossible to use human samples for studying the role of SOD1 in the genesis and development of human epilepsy due to ethic limitation. Therefore, animal models with epilepsy will be further tested for the mechanisms of epileptogenesis based on SOD1 alterations.
The present study indicates that SOD1 has been markedly decreased in the CSF of patients with intractable epilepsy compared to the CSF of patients with epilepsy. Therefore, CSF-SOD1 alterations can probably be used as a predicting factor for intractable epilepsy; epileptic patients with decreased CSF-SOD1 are apt to be drug-resistant. However, no reference value is concluded to distinguish intractable epilepsy and drug-effective epilepsy due to the limited sample size. In addition, the role of serum-SOD1 change is different compared to CSF-SOD1 change, we thus think that peripheral SOD1 does not reflect the change in the central environment. Further study will be performed to expand the samples to confirm the reference value for the diagnosis of intractable epilepsy.
In conclusion, SOD1 levels are decreased in the CSF of human epilepsy. Decreased levels of SOD1 are associated with repeated seizures. Therefore, decreased CSF-SOD1 might be a potential factor for predicting intractable epilepsy.
